The Committee reviewed an application submitted by Aventis Behring, GmbH, Marburg Germany, to remove the 100000 IU dosage form of streptokinase from the Model List. The Committee noted that the recommended standard dosage for streptokinase’s main indication, the treatment of acute myocardial infarction, is 1.5 million IU. The Committee recommended that the dosage form for streptokinase be changed to: powder for injection, 1.5 million IU in vial and that the note, “For use in rare or exceptional circumstances.” be removed since its value in treating acute myocardial infarction is now well established and its use is no longer reserved for exceptional situations. The Committee recommended that the dosage form for streptokinase be changed to powder for injection, 1.5 million IU in vial and that the existing footnote, “For use in rare disorders or in exceptional circumstances.” be removed.